Last reviewed · How we verify
Neuromyelitis optica
Approved treatments
- Mabthera · Roche
- H5G1.1 · AstraZeneca
Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation. - UPLIZNA · VIELA BIO
- Uplizna · Viela Bio
Uplizna works by binding to CD19 on B-lymphocytes, marking them for destruction. - Mabthera · Roche
Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC. - Mabthera · Roche
Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction. - Soliris · Apellis Pharmaceuticals, Inc.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Neuromyelitis optica patent landscape — cliff calendar, originator estates, attackable patents
- Neuromyelitis optica treatment landscape brief
- Neuromyelitis optica treatment updates RSS
Frequently asked questions about Neuromyelitis optica
What drugs treat Neuromyelitis optica?
Tracked treatments include Mabthera, H5G1.1, UPLIZNA, Uplizna, Soliris.
What is the treatment for Neuromyelitis optica?
Standard treatment for Neuromyelitis optica includes Mabthera, H5G1.1, UPLIZNA, Uplizna, Soliris. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Neuromyelitis optica patent cliff · Neuromyelitis optica CI report
- Treatment: Mabthera · Roche
- Treatment: H5G1.1 · AstraZeneca
- Treatment: UPLIZNA · VIELA BIO
- Treatment: Uplizna · Viela Bio
- Treatment: Mabthera · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing